Novartis says that the decision touches Intellectual Property
principles in all sectors of the country.
Everything seemed that the declaration of the Imatinib molecule
to treat cancer as a matter of public interest, would be the third
case of compulsory license in Latin America, after the governments
of Brazil and Ecuador made use of this power in the past .
Remember that in 2007 the Brazilian government granted a
compulsory license for the manufacture of antiretroviral efavirenz,
whose patent belongs to Merck Sharp & Dohme. Meanwhile, in 2010
the Government of Ecuador issued a compulsory license allowing the
import of ritonavir antiretroviral drug manufacturer Cipla Indian
pharmaceutical generic drugs whose patent holder is Abbott.
Being a pre Compulsory license in most of the laws providing for
caning law requirement, like what has happened in Colombia with the
Imatinib molecule to treat cancer, both in the case of Brazil and
Ecuador was negotiated previously and unsuccessfully with the
holders of the respective patents, to lower prices, arguing
facilitate drug access to most of the population, given its high
However, in this case, after failed negotiations with the Swiss
drugmaker Novartis, the Ministry of Health of Colombia has decided
not to grant compulsory license to another (s) manufacturer (s) of
the drug or to allow the import of a generic of the same active
ingredient of the drug to a foreign laboratory, but has decided to
set the sales price of the drug through an administrative act for
the National Commission on drug Pricing and devices define
unilaterally the amount of the drug, simulating conditions of
This government decision have not been controversy-free since,
although we are against the use of flexibilities to patent
protection, provided for in Article 31 of the Agreement on Aspects
of Intellectual Intellectual Property Related Trade (TRIPS), this
is an "exception" that must be given under certain
conditions and if certain circumstances are referred to in the
domestic laws of each country.
This is how the president of Novartis for the Andean region has
been demonstrated in total disagreement with the measure, pointing
out that the conditions are not pricing in this case. And the risk
of such decisions, it can be seen by the owners of companies
engaged in research as a bad sign, it is necessary to understand
the exceptional nature should have pricing and / or compulsory
licensing, and used by the current government, as a tool for saving
medicines or intimidation when negotiating with patent holders.
A Clarke, Modet & Cº Brasil com o intuito de disseminar a importância da Propriedade Intelectual no ambiente inovador dentro das Universidades é uma das patrocinadoras do Desafio Unicamp de Inovação Tecnológica.
O evento idealizado pela Agência de Inovação Inova Unicamp é destinado a estudantes de graduação e pós–graduação e interessados em empreendedorismo tecnológico de todo país, e possui como objetivo principal gerar, através da competição de modelo de negócios, empresas de base tecnológica a partir da propriedade intelectual criada na Universidade.
No dia 04 de maio de 2017 a Clarke, Modet & Cº Brasil terá o prazer de realizar o Encontro Anual de Mulheres de PI, da AIPLA, no Brasil.
“The Annual worldwide Women in IP Networking Event” é um momento único, que conta com a participação de mulheres da área de Propriedade Intelectual, ou mulheres que estão envolvidas com o tema, em todo o mundo.
As participantes se conectarão com mais de 50 países ao redor do mundo, via teleconferência.
No Brasil, o evento acontecerá em São Paulo, no Sheraton WTC Hotel, das 18 às 20 horas, com um coquetel de encerramento até as 21 horas.
Nossa Diretora Corporativa de Serviços Técnicos e Jurídicos, Daniela Fasoli e outras mulheres representativas da área, falarão sobre os desafios e conquistas das mulheres de PI no ambiente empresarial e dividirão um pouco de sua experiência com os presentes.
Mexico is a civil law country, meaning that the Mexican system does not rely on stare decisis or considers case law as binding precedent. As a result, the Mexican intellectual property statues are significantly more detailed than their US compliments.
Current Intellectual Property Law No. 9,279 of May 14, 1996 and the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement allow for patenting of pharmaceuticals in Brazil. Notwithstanding, in 2001, the Brazilian IP Law was amended and the prosecution of pharmaceutical patent applications changed substantially.
Owners of intellectual property (IP) have many ways to protect their valuable assets.
Some comments from our readers… “The articles are extremely timely and highly applicable” “I often find critical information not available elsewhere” “As in-house counsel, Mondaq’s service is of great value”
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).